Sanofi has announced plans to launch a “powerhouse” active pharmaceutical ingredient manufacturing company aimed at helping avert shortages of key drug raw materials in Europe and elsewhere and balance the pharmaceutical industry’s heavy reliance on essential molecules sourced from Asia.
The Paris-based drugmaker said the plans to set up what it says will be the world’s second-largest API manufacturing company have been in the works for a while and are not linked to the unfolding coronavirus epidemic
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?